AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Castle Biosciences Inc (NASDAQ:CSTL)
21.01 USD
-0.590 2.732%Sponsored Reports
Loading...
| Previous Close (in USD) | 21.6 |
|---|---|
| Change | -0.590 2.732% |
| 52 W H/L (in USD) | 44.280/14.590 |
| EBITDA (in USD) | -2.039M |
| PE Ratio | -- |
| Volume | 212464 |
| Diluted Eps TTM | -0.83 |
| Total Assets (in USD) | 578.556M |
|---|---|
| Total Liabilities (in USD) | 107.683M |
| Revenue TTM (in USD) | 344.229M |
| Cash (in USD) | 116.729M |
| Market Cap (in USD) | 744.675 M |
| Revenue Per Share TTM | 11.876 |
| Gross Profit TTM (in USD) | 273.201M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Castle Biosciences Inc
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
1500 W. Parkwood Ave, Friendswood, TX, United States, 77546
866 788 9007
Employees: 883
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Derek J. Maetzold | Founder, CEO, Pres & Director | 1962 |
| 2. | Mr. Frank Stokes | CFO & Treasurer | 1970 |
| 3. | Ms. Kristen M. Oelschlager R.N., RN | Chief Operating Officer | 1968 |
| 4. | Mr. Toby W. Juvenal | Chief Commercial Officer | 1961 |
| 5. | Camilla Zuckero | Exec. Director of Investor Relations & Corp. Communications | NA |
| 6. | Ms. Alice Bahner Izzo | Sr. VP of Marketing | NA |
| 7. | Ms. Keli Greenberg | VP of HR & Exec. Director of HR | NA |
| 8. | Dr. Robert W. Cook Ph.D. | Sr. VP of R&D | 1972 |
| 9. | Mr. Bernhard E. Spiess | Company Sec. | 1960 |
| 10. | Mr. John W. Abbott | VP & Controller | NA |
Peers
Sector: Healthcare
Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
TMO
Thermo Fisher Scientific Inc |
-9.230 1.915% | 484.22 | 34.710 | 23.866 | 4.622 | 4.428 | 5.293 | 20.886 |
|
DHR
Danaher Corporation |
-2.340 1.254% | 188 | 29.090 | 28.011 | 5.669 | 3.198 | 5.999 | 19.094 |
|
A
Agilent Technologies Inc |
-2.930 2.118% | 137.95 | 34.360 | 26.385 | 6.587 | 7.136 | 6.781 | 23.557 |
|
IDXX
IDEXX Laboratories Inc |
-2.580 0.457% | 567.07 | 49.990 | 45.662 | 11.293 | 27.850 | 11.461 | 34.457 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -29.514M | 21.564M | -57.365M | -68.904M | -40.012M |
| Minority Interest | - | - | - | - | - |
| Net Income | -24.158M | 18.245M | -57.466M | -67.138M | -31.292M |
| Selling General Administrative | 229.323M | 76.58M | 66.495M | 143.003M | 86.738M |
| Gross Profit | 236.346M | 271.864M | 174.806M | 105.03M | 78.263M |
| Reconciled Depreciation | 40.771M | 15.997M | 11.947M | 10.543M | 3.407M |
| Ebit | -29.428M | 22.141M | -57.354M | -91.142M | -40.079M |
| Ebitda | 11.343M | 38.138M | -45.024M | -76.631M | -36.604M |
| Depreciation And Amortization | 40.771M | 15.997M | 12.33M | 14.511M | 3.475M |
| Operating Income | -42.81M | 8.67M | -67.977M | -91.142M | -40.079M |
| Other Operating Expenses | 387.039M | 323.399M | 287.765M | 228.181M | 134.164M |
| Interest Expense | 0.086M | 0.577M | 0.011M | 0.017M | 0.001M |
| Tax Provision | -5.356M | 3.319M | 0.119M | -1.766M | -8.72M |
| Interest Income | 11.772M | 12.916M | 9.779M | 3.968M | 0.068M |
| Net Interest Income | 11.686M | 12.339M | 9.766M | 3.951M | 0.067M |
| Income Tax Expense | -5.356M | 3.319M | 0.101M | -1.766M | -8.72M |
| Total Revenue | 344.229M | 332.069M | 219.788M | 137.039M | 94.085M |
| Total Operating Expenses | 279.156M | 263.194M | 242.783M | 196.172M | 118.342M |
| Cost Of Revenue | 107.883M | 60.205M | 44.982M | 32.009M | 15.822M |
| Total Other Income Expense Net | 13.296M | 12.894M | 10.612M | 22.238M | 0.067M |
| Net Income From Continuing Ops | -24.158M | 18.245M | -75.504M | -67.138M | -31.292M |
| Net Income Applicable To Common Shares | - | - | - | -67.138M | -31.292M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 578.556M | 531.235M | 477.811M | 447.329M | 462.572M |
| Intangible Assets | 88.882M | 95.537M | 106.643M | 115.656M | 88.922M |
| Other Current Assets | 7.956M | 7.671M | 6.292M | 6.207M | 4.807M |
| Total Liab | 107.683M | 75.4M | 86.542M | 48.179M | 50.832M |
| Total Stockholder Equity | 470.873M | 455.835M | 391.269M | 399.15M | 411.74M |
| Other Current Liab | 48.224M | 39.472M | 36.262M | 29.62M | 21.161M |
| Common Stock | 0.03M | 0.028M | 0.027M | 0.027M | 0.025M |
| Capital Stock | 0.03M | 0.028M | 0.027M | 0.027M | 0.025M |
| Retained Earnings | -224.284M | -200.126M | -218.371M | -160.905M | -93.767M |
| Good Will | 99.574M | 10.692M | 10.692M | 10.692M | - |
| Other Assets | - | - | - | 2.197M | 3.023M |
| Cash | 116.729M | 119.709M | 98.841M | 122.948M | 329.633M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 68.677M | 49.392M | 47.667M | 36.128M | 24.886M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -79.816M | -93.365M | -83.531M | -109.638M | -321.554M |
| Short Term Debt | 1.742M | 1.943M | 1.137M | 1.777M | 1.179M |
| Short Long Term Debt | 0.417M | 0.278M | - | - | - |
| Short Long Term Debt Total | 36.913M | 26.344M | 15.31M | 13.31M | 8.079M |
| Other Stockholder Equity | 694.86M | 655.703M | 609.477M | 560.409M | 505.482M |
| Property Plant Equipment | - | - | - | 26.496M | 16.884M |
| Total Current Assets | 361.097M | 360.154M | 295.635M | 292.288M | 353.743M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 182.776M | 173.421M | 144.258M | 135.677M | - |
| Net Receivables | 43.382M | 51.218M | 38.302M | 23.476M | 17.282M |
| Long Term Debt | 9.64M | 9.745M | - | - | - |
| Inventory | 10.254M | 8.135M | 7.942M | 3.98M | 2.021M |
| Accounts Payable | 18.711M | 6.901M | 10.268M | 4.731M | 2.546M |
| Accumulated Other Comprehensive Income | 0.267M | 0.23M | 0.136M | -0.381M | - |
| Non Currrent Assets Other | 5.647M | 2.146M | 1.44M | 2.197M | 3.023M |
| Non Current Assets Total | 217.459M | 171.081M | 182.176M | 155.041M | 108.829M |
| Capital Lease Obligations | 26.856M | 16.321M | 15.335M | 13.31M | 8.079M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | 2.019M | -50.137M | -12.993M | -166.545M | -66.657M |
| Total Cashflows From Investing Activities | -60.367M | -50.137M | -16.183M | -166.545M | -66.657M |
| Total Cash From Financing Activities | -6.96M | 6.139M | -2.298M | 1.515M | 5.421M |
| Net Income | -24.158M | 18.245M | -57.466M | -67.138M | -31.292M |
| Change In Cash | -2.98M | 20.868M | -24.107M | -206.685M | -80.219M |
| Begin Period Cash Flow | 119.709M | 98.841M | 122.948M | 329.633M | 409.852M |
| End Period Cash Flow | 116.729M | 119.709M | 98.841M | 122.948M | 329.633M |
| Total Cash From Operating Activities | 64.347M | 64.866M | -5.626M | -41.655M | -18.983M |
| Depreciation | 40.771M | 15.997M | 12.33M | 10.543M | 3.407M |
| Other Cashflows From Investing Activities | -7.638M | 0.018M | 0.013M | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -2.142M | -0.193M | -3.962M | -1.68M | 0.327M |
| Sale Purchase Of Stock | - | - | -5.134M | - | - |
| Other Cashflows From Financing Activities | -9.051M | -5.781M | -2.156M | 0.804M | 5.429M |
| Capital Expenditures | 36.021M | 28.326M | 13.621M | 5.632M | 3.483M |
| Change In Working Capital | 13.601M | -14.125M | -6.63M | -0.007M | -4.102M |
| Other Non Cash Items | -5.532M | -6.972M | -4.856M | -19.497M | 75.759M |
| Free Cash Flow | 28.326M | 36.54M | -19.247M | -47.287M | -22.466M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Principal U.S. Small Cap Equity | 5 months ago | 834438 |
| 2. | Principal U.S. Small Cap Select Equity | 5 months ago | 834438 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 823964 |
| 4. | Principal SmallCap R5 | 3 months ago | 762438 |
| 5. | iShares Russell 2000 ETF | 2 months ago | 700151 |
| 6. | Strategic Advisers U.S. Total Stock | 3 months ago | 664357 |
| 7. | Palisade Small Cap Core Equity | 5 months ago | 379131 |
| 8. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 325759 |
| 9. | Eventide Healthcare & Life Sciences I | 5 months ago | 305000 |
| 10. | Vanguard Explorer Inv | 5 months ago | 275891 |
| 11. | Wasatch Ultra Growth | 5 months ago | 275188 |
| 12. | Fidelity Small Cap Index | 4 months ago | 275061 |
| 13. | Wasatch Micro Cap | 5 months ago | 253777 |
| 14. | iShares Russell 2000 Value ETF | 2 months ago | 248259 |
| 15. | Kornitzer Small Cap Equity | 5 months ago | 239614 |
| 16. | Buffalo Small Cap Growth | 5 months ago | 239614 |
| 17. | iShares Biotechnology ETF | 2 months ago | 216137 |
| 18. | Nuveen Quant Small Cap Equity R6 | 3 months ago | 194750 |
| 19. | Russell 2000 Equity Index Fund B | 5 months ago | 176078 |
| 20. | State St Russell Sm/Mid Cp® Indx SL Cl I | 2 months ago | 171130 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BlackRock Inc | 8 months ago | 3189896 |
| 2. | Vanguard Group Inc | 5 months ago | 2199829 |
| 3. | RTW INVESTMENTS, LLC | 5 months ago | 2115237 |
| 4. | Principal Financial Group Inc | 8 months ago | 1794355 |
| 5. | Portolan Capital Management, LLC | 5 months ago | 1729463 |
| 6. | Dimensional Fund Advisors, Inc. | 5 months ago | 1143799 |
| 7. | Summit Partners Public Asset Management, LLC | 5 months ago | 1058725 |
| 8. | State Street Corp | 8 months ago | 724080 |
| 9. | Geode Capital Management, LLC | 5 months ago | 714913 |
| 10. | AIGH Capital Management, LLC | 5 months ago | 624719 |
| 11. | Allianz Asset Management AG | 5 months ago | 622299 |
| 12. | Palisade Capital Management LLc | 5 months ago | 567777 |
| 13. | Wasatch Advisors LP | 5 months ago | 537241 |
| 14. | Nuveen, LLC | 5 months ago | 524681 |
| 15. | Renaissance Technologies Corp | 5 months ago | 493100 |
| 16. | Schroder Investment Management Group | 5 months ago | 492161 |
| 17. | Connor Clark & Lunn Inv Mgmt Ltd | 5 months ago | 388491 |
| 18. | Citadel Advisors Llc | 5 months ago | 366356 |
| 19. | Bank of America Corp | 8 months ago | 315370 |
| 20. | Millennium Management LLC | 5 months ago | 308914 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...